Back to search

Article

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells

2025-07-15

Abstract excerpt

<title>Abstract</title> <p> <bold>Purpose</bold> : PARP inhibitors have been approved for treating a subset of breast cancer patients harboring <italic>BRCA1/2</italic> mutations. However, TNBC patients with wildtype <italic>BRCA1/2</italic> have limited targeted therapeutic options. Dysregulation of protein arginine methyltransferase 5 (PRMT5) has been implicated in the progression of various cancers, incl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
04afc2ef-82bd-5f86-b8f6-cc6709c90095
DOI
10.21203/rs.3.rs-6959243/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsDOI 10.21203/rs.3.rs-6959243/v1
Efficacy and Mechanism of the Combination of PARP&nbsp;and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity
DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic reviewSemantic proximity
Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentSemantic proximity
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity
A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerSemantic proximity
Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: An updated systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Update on Combination Strategies of PARP InhibitorsSemantic proximity
Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: An updated systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Development of the PARP inhibitor talazoparib for the treatment of advancedBRCA1andBRCA2mutated breast cancerSemantic proximity
PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant CancersSemantic proximity
Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cellsSemantic proximity
Select a neighboring publication to make it the new centre.